RESUMEN
Methocarbamol is an antispasmodic muscle relaxant and was the fourth most-prescribed muscle relaxant by volume in the United States in 2021. Intravenous (IV) methocarbamol contains the excipient, polyethylene glycol (PEG), which has been implicated in metabolic acidosis and nephrotoxicity. Intravenous methocarbamol was first approved by the US Food and Drug Administration in 1959 and at that time the IV methocarbamol prescribing information warned of PEG-associated adverse drug events in patients living with renal impairment; however, the manufacturer acknowledged data were lacking to objectively support this claim. Clinicians prescribing and dispensing IV methocarbamol may encounter the warning for PEG-associated metabolic acidosis and nephrotoxicity without knowing the potential risks, or lack thereof, supporting or disavowing this phenomenon. This commentary debates the merits supporting and arguments refuting PEG-associated metabolic acidosis and nephrotoxicity in patients treated with IV methocarbamol.
Asunto(s)
Metocarbamol , Polietilenglicoles , Humanos , Metocarbamol/administración & dosificación , Metocarbamol/efectos adversos , Polietilenglicoles/administración & dosificación , Polietilenglicoles/efectos adversos , Acidosis/inducido químicamente , Administración Intravenosa , Enfermedades Renales/inducido químicamente , Excipientes/efectos adversosRESUMEN
BACKGROUND: To compare the 4-week effectiveness and tolerability of an add-on treatment with oral high dose methocarbamol (MET) vs long-acting oral opioid analgesics (LAO) in patients with non-specific low back pain (nsLBP) poorly responsive to recommended 1st line treatments. METHODS: Analysis of anonymized, propensity score-matched real-world data from the German Pain e-Registry, using a sequential non-inferiority superiority approach, for adult outpatients with nsLBP who had initiated treatment with MET or LAO between 1st January 2018 and 31st December 2019 (EUPAS identifier: 38484). The primary effectiveness variable was the absolute change of the average 24-h. pain intensity index (PIX). Safety was assessed by incidence of physician-confirmed drug-related adverse events (DRAEs), and DRAEs leading to discontinuation. RESULTS: Propensity score-matched data were analyzed for 374 patients treated with MET and 374 patients treated with LAO. Mean ± SD (median) MET dose over the 4-week evaluation period was 2390.4 ± 1980 (3000) mg and 69.6 ± 25.9 (60) mg morphine equivalent for LAO. With 25.8 ± 11.4 (median 26, 95%CI: 24.5-27.1) vs. 11.4 ± 6.8 (median 11; 95%CI: 10.6-12.2) mm VAS, absolute 4-week improvement vs. baseline was superior for MET vs. LAO [p < .001; effect size 1.6; least square mean difference 14.4 (95%CI: 13.4-15.3)]. Percentages of patients with a PIX improvement ≥ MCID was 81.8 vs. 24.6% [p < .001; OR: 13.8 (9.7-19.6), RR: 4.0 (3.2-5.0), NNT: 1.7]. A significantly lower number of patients treated with MET vs. LAO reported DRAEs in response to study medication: 36 (9.6%) vs. 139 (37.2%; p < .001; NNT 4), and 9 patients treated with MET (2.4%) vs. 86 (23.0%) treated with LAO discontinued treatment in response to these DRAEs (p < .001; NNT: 5). CONCLUSION: 4-week add-on treatment with MET in patients with nsLBP who showed an inadequate response to recommended 1st line treatments is superior effective to LAO and significantly better tolerated.KEY MESSAGESLow back pain is the most common musculoskeletal problem worldwide.In the majority of patients, LBP does not have a specific cause and the most prevalently coded form is mechanical, non-specific (ns) LBP associated with muscular tension, restrictions in mobility, and static malposition.Current treatment recommendations for nsLBP are largely "non-specific" as well, limited to symptomatic pain-relieving measures.In our propensity score-matched two cohort analyses of depersonalized real-world data from the German Pain e-Registry, a 4-week treatment with the muscle relaxant methocarbamol proved superior effective and significantly better tolerated than treatment with oral long-acting opioid analgesics in patients who poorly responded to recommended 1st line treatments.
Asunto(s)
Analgésicos Opioides , Dolor de la Región Lumbar , Metocarbamol , Adulto , Analgésicos/uso terapéutico , Analgésicos Opioides/efectos adversos , Humanos , Dolor de la Región Lumbar/tratamiento farmacológico , Metocarbamol/efectos adversos , Puntaje de Propensión , Sistema de Registros , Estudios Retrospectivos , Resultado del TratamientoAsunto(s)
Catatonia/fisiopatología , Infecciones por Coronavirus/fisiopatología , Deluciones/fisiopatología , Alucinaciones/fisiopatología , Hipnóticos y Sedantes/uso terapéutico , Lorazepam/uso terapéutico , Neumonía Viral/fisiopatología , Adulto , Antibacterianos/efectos adversos , Azitromicina/efectos adversos , Betacoronavirus , COVID-19 , Catatonia/complicaciones , Catatonia/tratamiento farmacológico , Catatonia/psicología , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/psicología , Deluciones/complicaciones , Deluciones/tratamiento farmacológico , Deluciones/psicología , Alucinaciones/complicaciones , Alucinaciones/tratamiento farmacológico , Alucinaciones/psicología , Humanos , Masculino , Metocarbamol/efectos adversos , Relajantes Musculares Centrales/efectos adversos , Pandemias , Neumonía Viral/complicaciones , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/psicología , SARS-CoV-2 , Espasmo/tratamiento farmacológicoRESUMEN
BACKGROUND: Muscle cramps occur in 29-88% of patients with liver cirrhosis. They adversely affect quality of life. This study aimed to evaluate the efficacy and safety of methocarbamol as a novel therapy in controlling muscle cramps in cirrhotic patients. PATIENTS AND METHODS: This study was carried on 100 patients with liver cirrhosis in addition to chronic hepatitis C who presented with frequent muscle cramps (≥three cramps per week). Half of these patients received methocarbamol and the other half received placebo. This was done through equal randomization. Questionnaires on muscle cramp were answered. Patients were evaluated before, after 1 month of treatment, and 2 weeks after washout of treatment in terms of severity, duration, and frequency of cramps. Liver, renal functions, and electrolytes were analyzed. Also, any side effect was detected. RESULTS: Patients who were treated with methocarbamol showed a significant decrease in the frequency and duration of cramps. Also, the pain score improved significantly. However, no significant changes were observed in the placebo group. Few side effects of methocarbamol were recorded, including dry mouth and drowsiness. CONCLUSION: Methocarbamol seems to be a promising safe and well-tolerated medication, and plays a role in the treatment of muscle cramps in patients with liver cirrhosis.
Asunto(s)
Cirrosis Hepática/complicaciones , Metocarbamol/uso terapéutico , Calambre Muscular/tratamiento farmacológico , Relajantes Musculares Centrales/uso terapéutico , Adulto , Anciano , Método Doble Ciego , Femenino , Hepatitis C Crónica/complicaciones , Humanos , Cirrosis Hepática/virología , Masculino , Metocarbamol/efectos adversos , Persona de Mediana Edad , Calambre Muscular/etiología , Relajantes Musculares Centrales/efectos adversos , Dolor/prevención & control , Resultado del TratamientoRESUMEN
Descriptive case report of a 42-year old woman with coetaneous vasculitis, and severe abdominal pain, which was led to diagnostic laparotomy. These presentations are probably as a side effect of Methocarbamol injection. This is the first report according to our literature search (PubMed, google scholar, ISI web of knowledge, ProQuest, MD consult, Science Direct, SCOPUS) about Methocarbamol related vasculitis from 1966 since now. Vasculitis is not a known side effect of Methocarbamol. This case indicates, likely the potential for development of vasculitis with this medication.
Asunto(s)
Metocarbamol/efectos adversos , Relajantes Musculares Centrales/efectos adversos , Vasculitis Leucocitoclástica Cutánea/inducido químicamente , Abdomen Agudo/inducido químicamente , Adulto , Femenino , Humanos , Piel/patología , Vasculitis Leucocitoclástica Cutánea/patologíaRESUMEN
For patients and their loved ones, delirium can be a frightening experience. A fluctuating mental status is important to identify because it often signals a need for additional treatment. The Confusion Assessment Method (CAM) diagnostic algorithm enables nurses to assess for delirium by identifying the four features of the disorder that distinguish it from other forms of cognitive impairment. It can be completed in five minutes and is easily incorporated into ongoing assessments of hospitalized patients. (This screening tool is included in the series Try This: Best Practices in Nursing Care to Older Adults, from the Hartford Institute for Geriatric Nursing at New York University's College of Nursing.) For a free online video demonstrating the use of this tool, go to http://links.lww.com/A209.
Asunto(s)
Analgésicos Opioides/efectos adversos , Trastornos de la Percepción Auditiva , Confusión , Delirio/diagnóstico , Hidromorfona/efectos adversos , Metocarbamol/efectos adversos , Agitación Psicomotora , Algoritmos , Delirio/inducido químicamente , Delirio/enfermería , Humanos , Masculino , Relajantes Musculares Centrales/efectos adversos , Reproducibilidad de los ResultadosRESUMEN
Submuscular placement of breast implants produces significant postoperative pain and discomfort. The standard use of narcotics alone does not optimize pain reduction. Methocarbamol was used intraoperatively and postoperatively in 62 patients undergoing manipulation of the pectoralis major associated with breast implant surgery. Significant pain relief was achieved.
Asunto(s)
Implantes de Mama , Metocarbamol/administración & dosificación , Relajantes Musculares Centrales/administración & dosificación , Dolor Postoperatorio/tratamiento farmacológico , Adulto , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Humanos , Metocarbamol/efectos adversos , Relajantes Musculares Centrales/efectos adversos , Dimensión del Dolor , Dolor Postoperatorio/etiologíaRESUMEN
The clinical manifestations of colonic urticaria vary, depending on the presence of associated abnormalities. A case of an association between colonic urticaria and cecal volvulus is described.
Asunto(s)
Enfermedades del Ciego/complicaciones , Enfermedades del Colon/diagnóstico por imagen , Obstrucción Intestinal/complicaciones , Urticaria/diagnóstico por imagen , Enfermedades del Colon/inducido químicamente , Enfermedades del Colon/complicaciones , Hipersensibilidad a las Drogas/complicaciones , Humanos , Obstrucción Intestinal/diagnóstico por imagen , Masculino , Metocarbamol/efectos adversos , Persona de Mediana Edad , Radiografía , Tioridazina/efectos adversos , Urticaria/inducido químicamente , Urticaria/complicacionesAsunto(s)
Acetaminofén/uso terapéutico , Aspirina/uso terapéutico , Benzoxazoles/uso terapéutico , Clorzoxazona/uso terapéutico , Metocarbamol/uso terapéutico , Enfermedades Musculares/tratamiento farmacológico , Acetaminofén/administración & dosificación , Acetaminofén/efectos adversos , Adolescente , Adulto , Anciano , Aspirina/administración & dosificación , Aspirina/efectos adversos , Clorzoxazona/administración & dosificación , Clorzoxazona/efectos adversos , Ensayos Clínicos como Asunto , Combinación de Medicamentos , Femenino , Humanos , Masculino , Metocarbamol/administración & dosificación , Metocarbamol/efectos adversos , Persona de Mediana EdadRESUMEN
A double-blind trial of methocarbamol versus placebo was carried out in 59 matched pairs of patients suffering from painful muscle spasm. Methocarbamol (1500 mg. q.d.s.) was found to be effective in approximately 60% of patients compared with 30% of patients receiving placebo (p less than 0.01). Side-effects were of almost equal incidence in the two groups.